Left Ventricular Systolic DysfunctionNCT02642770
3D & Speckle Tracking Together as a Marker for Early Outcome in Cardiac Surgery
An observational study of Left Ventricular Systolic Dysfunction, run by Post Graduate Institute of Medical Education and Research, Chandigarh at 1 site in India.
Trial summary
Patients presenting with Left Ventricle (LV) dysfunction undergoing cardiac surgery are at increased risk of perioperative morbidity and mortality. LV dysfunction has been reported as an independent predictor of operative mortality in patients undergoing Cardiac surgery. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Left Ventricular Systolic Dysfunction
- What is being tested?
- Transesophageal echocardiography
- Type of treatment
- Medical device
- How many people
- 73 participants
- Where
- 1 siteIndia
- Study dates
- Aug 2015to Sep 2016
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients with left ventricular dysfunction (LVEF< 50%) undergoing cardiac surgery under CPB.
Who may be able to join
- Adult patients (>18yrs) with moderate to severe LV dysfunction (EF< 50%) planned for Coronary artery bypass graft (CABG) and/or valve repair/replacement, presenting to our center for elective or emergent surgery will be included in the study.
Who cannot join
- Hypertrophic cardiomyopathy
- Sepsis
- Preoperative renal impairment (serum creatinine 2.0 mg/ dL)
- Off pump CABG
- Redo surgery.
- Failed placement despite 3-4 attempts.
- Congenital heart lesions
Trial locations and contacts
1 site in 1 country.
About this study
Official title: 3D & Speckle Tracking Together as a Sensitive Marker for Early Outcome in Patients With Left Ventricular Dysfunction Undergoing Cardiac Surgery
Patients presenting with Left Ventricle (LV) dysfunction undergoing cardiac surgery are at increased risk of perioperative morbidity and mortality. LV dysfunction has been reported as an independent predictor of operative mortality in patients undergoing Cardiac surgery. It also often leads to low cardiac output states with many of these patients requiring inotropic or mechanical support and vasopressors for hours to days after surgery. Speckle tracking when combined with three dimensional (3D) imaging techniques might prove to be a more sensitive marker for ventricular dysfunction. The present study investigates early outcomes in a consecutive series of patients with LV dysfunction undergoing cardiac surgery
Read the detailed description
All patients inside operating room, a wide bore i/v access and radial artery will be cannulated under local anesthesia. Standard opioid- propofol- relaxant based induction will be followed. After endotracheal intubation, an adult 2D Trans Eesophageal Echocardiography (TEE) probe (6VT-D probe of the GE vivid E9 echocardiography system (GE Medical Systems, Hortein, Norway) will be inserted. A 7 Fr triple lumen catheter and 8.5 Fr introducer sheath will be placed in the right internal jugular vein under ultrasound guidance. A 7 Fr Pulmonary Artery Catheter (PAC) (Swan Ganz catheter, Edwards Life Sciences) will be floated as per standard practice. Attempts to wedge will be discontinued if the catheter does not wedge beyond 8 cm into the main pulmonary artery.
Surgery will be performed through a midline sternotomy on cardiopulmonary bypass with bicaval cannulation and with intermittent antegrade warm blood cardioplegia. All surgical procedures were performed by experienced surgeons using standardized techniques.
Cardiopulmonary bypass (CPB) and anaesthesia management will be performed according to our standard operating procedures. Moderate hypothermic (28-32*C) CPB will be established with a non-pulsatile flow of 2,5 l/min/m2 and an arterial pressure > 60 mmHg without additional filtration. CPB will be primed with balanced electrolyte solution. Coagulation will be offset by 400 IU/kg heparin aiming at an Activated Clotting Time (ACT) > 480 seconds. Additionally, all patients will receive tranexamic acid 100mg/kg. Cardioplegic arrest will be induced and maintained by intermittent administration of ante grade potassium enriched solution.
Perioperative goal-oriented haemodynamic support (i.e. heart rate 80-100 beats/min, mean arterial pressure 65-85 mmHg, central venous pressure (CVP) 8-12 mmHg at positive end-expiratory pressure 5 cms of water, pulmonary artery occlusion pressure 12-15 mmHg, cardiac index >2.5 l /min/m2 2, stroke volume index >30 ml/m, mixed venous oxygen saturation >65) will be established according to institutional standards. Intraoperatively, patients will be monitored with transoesophageal echocardiography (6VT-D probe of the GE vivid E9 echocardiography system (GE Medical Systems, Hortein, Norway)) and a pulmonary artery catheter with or without continuous mixed venous oximetry measurement. In case of difficult CPB separation despite hemodynamic optimization, an intraaortic balloon pump (IABP) will be placed according to the team's assessment.
After chest closure, the patient will be transferred intubated and mechanically ventilated in the ICU. Patients will be kept sedated with morphine administration (20-40 mcg/kg/min) until cardiopulmonary stability is achieved, chest tube drainage is negligible (<100 ml/h), and the patient is judged to be extubated. If mechanical ventilation is required > 12 hours, sedation will be switched to midazolam (10-20 mcg/kg/min) combined with morphine (20-40 mcg/kg/min), and weaning from mechanical ventilation will be performed according to the standard operating procedures at our hospital. Hemodynamic optimization will be continuously accomplished according to the haemodynamic goals as mentioned above.
The decision for renal replacement therapy (RRT) will be taken in consultation with the department of nephrology and based on the following criteria: a) oliguria < 500 ml/dl and/or anuria < 100 ml/dl, b) metabolic acidosis, c) hyperkaliaemia, and d) uraemia.
Hemodynamic monitoring Once PAC is placed, baseline parameters will be recorded in mmHg. Pressure will be defined as Pulmonary systolic pressure peak (PAPs), mean pressure (PAPm), and Pulmonary Artery Wedge Pressure (PAWP).
These reading will be taken as baseline after placement of PAC. In addition usual vital parameters such as mean blood pressure (MAP), CVP and heart rate (HR), will also be acquired.
Systemic Vascular Resistance (SVR) and Cardiac Index (CI) calculation will be done as per the standard protocol.
Time periods at which parameters will be evaluated After induction of anesthesia hemodynamic and echocardiographic parameters will be taken. After induction, if the patients require ionotropes and/or vasopressors it will be administered to achieve the haemodynamic goal as mentioned above. The parameters will be obtained again after coming out of CPB. Patient will be started on vasopressors- inotropic support as deemed fit by the treating anaesthesiologist to achieve the haemodynamic goal.
End point of study: Either patient dies or discharged from the ICU as per the protocol.
Echocardiographic monitoring All patients in whom TEE probe is placed will undergo an initial comprehensive TEE examination covering all the 28 standard views as per the American Society of Echocardiography (ASE) guidelines. In addition, focused assessment for the study parameters will be done after the completion of comprehensive examination.
Assessment of LV Comprehensive echocardiography will be performed before surgery using 6VT-D probe of the GE vivid E9 echocardiography system (GE Medical Systems, Hortein, Norway), including standard 2D views digitally stored at a high frame rate (>50 frames/s). All measurements will be performed on line on the same machine by anaesthesiologist experienced in TEE blinded to patient's outcome. Left ventricle (LV) volumes in systole and diastole and LV Ejection Fraction (LVEF) will be computed using the Simpson biplane method from 2 chamber (2C) and 4 chamber (4C) apical views. The endocardial borders will be traced for the measurements and the papillary muscles will be excluded, as recommended in the guidelines. A frame rate of >50 will be ensured during the measurements to ensure accurate endocardial border detection. Foreshortening will be avoided by retroflexing the probe.
Speckle-tracking analysis will be performed to assess LV Global Longitudinal strain (GLS). GLS will be computed using 2D-speckle-tracking analysis by automated function imaging (AFI) measured from the three mid esophageal views (long-axis and two- and four-chamber views). For strain processing, the peak of the R-wave on the electrocardiogram will be used as the reference time point for end-diastole and segments with poor-quality tracking will be manually discarded. GLS will only be computed from patients with >14 segments adequately tracked for a 18-segment model. GLS will be calculated by averaging the peak strain values of 18 segments. Three-dimensional LV volumes and EF will be measured from the 3D full-volume data set. Using the on board GE software (GE vivid E9 echocardiography system (GE Medical Systems, Hortein, Norway), the full-volume data of the LV will be organized into orthogonal four-, two-chamber, and short-axis views. Enddiastolic and end-systolic frames will be selected. Mitral annular and apical points will be placed on these images by adjusting the axis. Semi-automated LV endocardial border detection software on the system will outline the endocardial borders in these three planes. The software then uses sequence analysis to track the endocardium in all frames and then automatically calculate a true 3D end diastolic volume (EDV), end systolic volume (ESV), and EF from the moving 3D endocardial shell. The endocardial borders could be adjusted manually if the endocardial border tracking is deemed inadequate, and the sequence analysis will be repeated.
The diastolic function of the LV will be measured by measuring these parameters- the mitral inflow velocity and the tissue Doppler velocity of the lateral mitral annulus. The mitral inflow velocities (E \& A) will be measured by placing the cursor for pulsed wave Doppler at the tip of the mitral leaflet coaptation point. The sweep speed will be set at 25mm/s and the scale will be adjusted and the baseline shifted above to obtain optimal waveforms. Tissue Doppler measurements will be taken by placing the cursor of pulsed wave tissue Doppler on the lateral mitral annulus. A frame rate of > 100m/s will be ensured by adjusting the sector width and the measurements made at a sweep aped of 25mm/s.
Post valve replacements, the prosthetic valves will be evaluated as per recommendations for evaluation of prosthetic valves. For all measurements of pulsed and continuous wave doppler the cursor will be placed at an angle < 20' to the flow.
Every attempt will be made to make measurements in sinus rhythm. In case of a non-sinus rhythm, measurements will be taken at the time when the ventricular rate is close to the baseline. If that is not possible, then an average of 5-6 readings will be used for analysis.
- Conditions
- Left Ventricular Systolic Dysfunction
- Being tested
- Transesophageal echocardiography
- Keywords
- Transesophageal echocardiography, Speckle tracking strain
- Medical subject headings
- Ventricular Dysfunction, Left
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Transesophageal echocardiographyDevice
2D LV Speckle tracking strain and 3D LVEF measurements
What is being measured
The primary outcome is the main question the study is designed to answer.
incidence of Low Cardiac Output Syndrome
Vassopressors Ionotropic Score (VIS) ≥ 15 (> 30 mins) or Requirement of Intra aortic balloon counterpulsation (IABP) in Intensive Care Unit.
Measured: 48 hrs
Secondary outcomes (1)
Duration of Mechanical Ventilation or Mortality
Measured: 5 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Dec 2015 (estimated)
- Study startAug 2015
- Primary completionSep 2016
- Study completionSep 2016
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Left Ventricular Systolic DysfunctionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 73 participants (actual)
Sponsor and investigators
- Lead sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Dr Alok Kumar, Post Graduate Institute of Medical Education and Research, Chandigarh
- Investigators
- GD Puri, Prof, Study chair, Post Graduate Institute of Medical Education and Research, Chandigarh
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02642770
- Sponsor's protocol ID
- NK/2440/DM/2266
- Status last verified
- Sep 2016
- First submitted
- 26 Dec 2015
- Last updated
- 28 Sep 2016
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- Undecided
Publications
Ding W, Ji Q, Shi Y, Ma R. Predictors of low cardiac output syndrome after isolated coronary artery bypass grafting. Int Heart J. 2015;56(2):144-9. doi: 10.1536/ihj.14-231. Epub 2015 Feb 23.
PubMed 25740396
Study at a glance
From the registry record, last updated by the sponsor on 28 Sep 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- 3D & Speckle Tracking Together as a Sensitive Marker for Early Outcome in Patients With Left Ventricular Dysfunction Undergoing Cardiac Surgery
- ClinicalTrials.gov ID
- NCT02642770
- Acronym / sponsor ID
- NK/2440/DM/2266
- Conditions
- Left Ventricular Systolic Dysfunction
- Keywords
- Transesophageal echocardiography, Speckle tracking strain
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 73 participants (actual)
- Lead sponsor
- Post Graduate Institute of Medical Education and Research, ChandigarhUniversity, hospital or other
- Study start
- Aug 2015
- Primary completion
- Sep 2016 (actual)
- Study completion
- Sep 2016 (actual)
- First posted
- 30 Dec 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Patients presenting with Left Ventricle (LV) dysfunction undergoing cardiac surgery are at increased risk of perioperative morbidity and mortality. LV dysfunction has been reported as an independent predictor of operative mortality in patients undergoing Cardiac surgery. It also often leads to low cardiac output states with many of these patients requiring inotropic or mechanical support and vasopressors for hours to days after surgery. Speckle tracking when combined with three dimensional (3D) imaging techniques might prove to be a more sensitive marker for ventricular dysfunction. The present study investigates early outcomes in a consecutive series of patients with LV dysfunction undergoing cardiac surgery
Detailed description
All patients inside operating room, a wide bore i/v access and radial artery will be cannulated under local anesthesia. Standard opioid- propofol- relaxant based induction will be followed. After endotracheal intubation, an adult 2D Trans Eesophageal Echocardiography (TEE) probe (6VT-D probe of the GE vivid E9 echocardiography system (GE Medical Systems, Hortein, Norway) will be inserted. A 7 Fr triple lumen catheter and 8.5 Fr introducer sheath will be placed in the right internal jugular vein under ultrasound guidance. A 7 Fr Pulmonary Artery Catheter (PAC) (Swan Ganz catheter, Edwards Life Sciences) will be floated as per standard practice. Attempts to wedge will be discontinued if the catheter does not wedge beyond 8 cm into the main pulmonary artery.
Surgery will be performed through a midline sternotomy on cardiopulmonary bypass with bicaval cannulation and with intermittent antegrade warm blood cardioplegia. All surgical procedures were performed by experienced surgeons using standardized techniques.
Cardiopulmonary bypass (CPB) and anaesthesia management will be performed according to our standard operating procedures. Moderate hypothermic (28-32*C) CPB will be established with a non-pulsatile flow of 2,5 l/min/m2 and an arterial pressure > 60 mmHg without additional filtration. CPB will be primed with balanced electrolyte solution. Coagulation will be offset by 400 IU/kg heparin aiming at an Activated Clotting Time (ACT) > 480 seconds. Additionally, all patients will receive tranexamic acid 100mg/kg. Cardioplegic arrest will be induced and maintained by intermittent administration of ante grade potassium enriched solution.
Perioperative goal-oriented haemodynamic support (i.e. heart rate 80-100 beats/min, mean arterial pressure 65-85 mmHg, central venous pressure (CVP) 8-12 mmHg at positive end-expiratory pressure 5 cms of water, pulmonary artery occlusion pressure 12-15 mmHg, cardiac index >2.5 l /min/m2 2, stroke volume index >30 ml/m, mixed venous oxygen saturation >65) will be established according to institutional standards. Intraoperatively, patients will be monitored with transoesophageal echocardiography (6VT-D probe of the GE vivid E9 echocardiography system (GE Medical Systems, Hortein, Norway)) and a pulmonary artery catheter with or without continuous mixed venous oximetry measurement. In case of difficult CPB separation despite hemodynamic optimization, an intraaortic balloon pump (IABP) will be placed according to the team's assessment.
After chest closure, the patient will be transferred intubated and mechanically ventilated in the ICU. Patients will be kept sedated with morphine administration (20-40 mcg/kg/min) until cardiopulmonary stability is achieved, chest tube drainage is negligible (<100 ml/h), and the patient is judged to be extubated. If mechanical ventilation is required > 12 hours, sedation will be switched to midazolam (10-20 mcg/kg/min) combined with morphine (20-40 mcg/kg/min), and weaning from mechanical ventilation will be performed according to the standard operating procedures at our hospital. Hemodynamic optimization will be continuously accomplished according to the haemodynamic goals as mentioned above.
The decision for renal replacement therapy (RRT) will be taken in consultation with the department of nephrology and based on the following criteria: a) oliguria < 500 ml/dl and/or anuria < 100 ml/dl, b) metabolic acidosis, c) hyperkaliaemia, and d) uraemia.
Hemodynamic monitoring Once PAC is placed, baseline parameters will be recorded in mmHg. Pressure will be defined as Pulmonary systolic pressure peak (PAPs), mean pressure (PAPm), and Pulmonary Artery Wedge Pressure (PAWP).
These reading will be taken as baseline after placement of PAC. In addition usual vital parameters such as mean blood pressure (MAP), CVP and heart rate (HR), will also be acquired.
Systemic Vascular Resistance (SVR) and Cardiac Index (CI) calculation will be done as per the standard protocol.
Time periods at which parameters will be evaluated After induction of anesthesia hemodynamic and echocardiographic parameters will be taken. After induction, if the patients require ionotropes and/or vasopressors it will be administered to achieve the haemodynamic goal as mentioned above. The parameters will be obtained again after coming out of CPB. Patient will be started on vasopressors- inotropic support as deemed fit by the treating anaesthesiologist to achieve the haemodynamic goal.
End point of study: Either patient dies or discharged from the ICU as per the protocol.
Echocardiographic monitoring All patients in whom TEE probe is placed will undergo an initial comprehensive TEE examination covering all the 28 standard views as per the American Society of Echocardiography (ASE) guidelines. In addition, focused assessment for the study parameters will be done after the completion of comprehensive examination.
Assessment of LV Comprehensive echocardiography will be performed before surgery using 6VT-D probe of the GE vivid E9 echocardiography system (GE Medical Systems, Hortein, Norway), including standard 2D views digitally stored at a high frame rate (>50 frames/s). All measurements will be performed on line on the same machine by anaesthesiologist experienced in TEE blinded to patient's outcome. Left ventricle (LV) volumes in systole and diastole and LV Ejection Fraction (LVEF) will be computed using the Simpson biplane method from 2 chamber (2C) and 4 chamber (4C) apical views. The endocardial borders will be traced for the measurements and the papillary muscles will be excluded, as recommended in the guidelines. A frame rate of >50 will be ensured during the measurements to ensure accurate endocardial border detection. Foreshortening will be avoided by retroflexing the probe.
Speckle-tracking analysis will be performed to assess LV Global Longitudinal strain (GLS). GLS will be computed using 2D-speckle-tracking analysis by automated function imaging (AFI) measured from the three mid esophageal views (long-axis and two- and four-chamber views). For strain processing, the peak of the R-wave on the electrocardiogram will be used as the reference time point for end-diastole and segments with poor-quality tracking will be manually discarded. GLS will only be computed from patients with >14 segments adequately tracked for a 18-segment model. GLS will be calculated by averaging the peak strain values of 18 segments. Three-dimensional LV volumes and EF will be measured from the 3D full-volume data set. Using the on board GE software (GE vivid E9 echocardiography system (GE Medical Systems, Hortein, Norway), the full-volume data of the LV will be organized into orthogonal four-, two-chamber, and short-axis views. Enddiastolic and end-systolic frames will be selected. Mitral annular and apical points will be placed on these images by adjusting the axis. Semi-automated LV endocardial border detection software on the system will outline the endocardial borders in these three planes. The software then uses sequence analysis to track the endocardium in all frames and then automatically calculate a true 3D end diastolic volume (EDV), end systolic volume (ESV), and EF from the moving 3D endocardial shell. The endocardial borders could be adjusted manually if the endocardial border tracking is deemed inadequate, and the sequence analysis will be repeated.
The diastolic function of the LV will be measured by measuring these parameters- the mitral inflow velocity and the tissue Doppler velocity of the lateral mitral annulus. The mitral inflow velocities (E \& A) will be measured by placing the cursor for pulsed wave Doppler at the tip of the mitral leaflet coaptation point. The sweep speed will be set at 25mm/s and the scale will be adjusted and the baseline shifted above to obtain optimal waveforms. Tissue Doppler measurements will be taken by placing the cursor of pulsed wave tissue Doppler on the lateral mitral annulus. A frame rate of > 100m/s will be ensured by adjusting the sector width and the measurements made at a sweep aped of 25mm/s.
Post valve replacements, the prosthetic valves will be evaluated as per recommendations for evaluation of prosthetic valves. For all measurements of pulsed and continuous wave doppler the cursor will be placed at an angle < 20' to the flow.
Every attempt will be made to make measurements in sinus rhythm. In case of a non-sinus rhythm, measurements will be taken at the time when the ventricular rate is close to the baseline. If that is not possible, then an average of 5-6 readings will be used for analysis.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with left ventricular dysfunction (LVEF< 50%) undergoing cardiac surgery under CPB.
Key inclusion criteria (1 listed)
- Adult patients (>18yrs) with moderate to severe LV dysfunction (EF< 50%) planned for Coronary artery bypass graft (CABG) and/or valve repair/replacement, presenting to our center for elective or emergent surgery will be included in the study.
Key exclusion criteria (7 listed)
- Hypertrophic cardiomyopathy
- Sepsis
- Preoperative renal impairment (serum creatinine 2.0 mg/ dL)
- Off pump CABG
- Redo surgery.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Transesophageal echocardiography2D LV Speckle tracking strain and 3D LVEF measurements | Device | – |
Primary outcome
incidence of Low Cardiac Output Syndrome
Time frame: 48 hrs
Vassopressors Ionotropic Score (VIS) ≥ 15 (> 30 mins) or Requirement of Intra aortic balloon counterpulsation (IABP) in Intensive Care Unit.
1 secondary outcome
Duration of Mechanical Ventilation or Mortality
Time frame: 5 days
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Sep 2016.
- Background: PubMed 25740396Ding W, Ji Q, Shi Y, Ma R. Predictors of low cardiac output syndrome after isolated coronary artery bypass grafting. Int Heart J. 2015;56(2):144-9. doi: 10.1536/ihj.14-231. Epub 2015 Feb 23.
- Individual participant dataSharing planned: Undecided
Related trials for Left Ventricular Systolic Dysfunction
RecruitingObservational study
Preoperative Gastric Ultrasound and Left Ventricular Function in Coronary Artery Bypass Surgery
Coronary Artery Disease, Left Ventricular Systolic Dysfunction
RecruitingPhase 2/3
Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)
Heart Failure, Left Ventricular Systolic Dysfunction
RecruitingPhase 3
A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction
Left Ventricular Systolic Dysfunction, Heart Failure (Pediatric)
Recruiting
The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy Trial (STICH3C)
Coronary Artery Disease, Heart Failure Systolic
RecruitingPhase 3
A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction
Left Ventricular Systolic Dysfunction, Heart Failure (Pediatric)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
GD Puri, Prof study chair
Post Graduate Institute of Medical Education and Research, Chandigarh
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Left Ventricular Systolic Dysfunction, run by Post Graduate Institute of Medical Education and Research, Chandigarh at 1 site in India.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 28 Sep 2016. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in India. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
incidence of Low Cardiac Output Syndrome (time frame: 48 hrs). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02642770, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Sep 2016.